drug
METHYLENE BLUE
Marketedupdated 3mo agoby Nexus Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(5)
approval · 5
Dec 5, 2023
approval
METHYLENE BLUE — FDA approval
METHYLENE BLUE
→
Mar 4, 2025
approval
METHYLENE BLUE — FDA approval
METHYLENE BLUE
→
Dec 23, 2025
approval
METHYLENE BLUE — FDA approval
METHYLENE BLUE
→
Feb 2, 2026
approval
METHYLENE BLUE — FDA approval
METHYLENE BLUE
→
Mar 31, 2026
approval
METHYLENE BLUE — FDA approval
METHYLENE BLUE
→
Trials studying METHYLENE BLUE
- —Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation
- phase1Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults
- —A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 8, 2027
140 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
FDA exclusivities (2)
- Jan 8, 2027M-303Method (3y)140d
- Jan 8, 2027M-303Method (3y)140d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that